Related Experiment Video
Updated: Aug 15, 2026
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
Published on: December 7, 2016
Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy
J Reche-Frutos1, C Calvo-Gonzalez, J Donate-Lopez
1Hospital Clinico Universitario San Carlos, Madrid, Spain. rechejuan@yahoo.es
Purpose:
To assess the short-term anatomic effect of intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Methods:
All patients had undergone a full ophthalmic examination. A monthly injection of ranibizumab was performed for 3 months. Indocyanine angiography (ICG) and optical coherence tomography (OCT) were performed 1 month after the third-month ranibizumab injection.
Results:
Polyps disappeared on ICG angiography in 9 out of 13 lesions (69.2%). Retinal thickness diminished significantly on OCT (p=0.02). In our series we noticed a significant reduction of the percentage of patients presenting with subretinal fluid (p=0.02) and pigment epithelium detachment between the initial and final visits (0.016). In addition, we noticed that BCVA increased significantly (p 0.02).
Conclusions:
Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect.
